Press Releases

– Trial designed to more comprehensively evaluate the effect of linaclotide 290 mcg on bothersome abdominal symptoms, including bloating, discomfort and pain, associated with IBS-C – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 16, 2018-- Ironwood Pharmaceuticals, Inc.

– Data provide additional evidence supporting development of praliciguat as a potential treatment for diabetic nephropathy and for heart failure with preserved ejection fraction – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 23, 2018-- Ironwood Pharmaceuticals, Inc.

– Program Designed to Support U.S. Regulatory Filing of IW-3718 as Potential Treatment for Patients Who Continue to Suffer From GERD Despite Receiving Standard of Care – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 21, 2018-- Ironwood Pharmaceuticals, Inc.

- Praliciguat Phase IIa data to be featured in an oral presentation - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 20, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced that the company will present clinical and preclinical data for the company’s

– Olinciguat Phase II trial in sickle cell disease continues to enroll patients – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 7, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Orphan

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 6, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13 th , 2018 at 4:00 p.m. Pacific Time ( 7:00 p.m.

– Also Evidence of Efficacy in Persistent GERD Patients with Erosive Esophagitis – – Additional Data Presented Further Highlight Role of Bile Acid in Persistent GERD – – Ironwood Expects to Advance IW-3718 into Phase III Trials in 3Q 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun.

Ironwood Shareholders Re-Elect All Three Ironwood Director Nominees CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 31, 2018-- Ironwood Pharmaceuticals , Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that, based on the vote count following the 2018 Annual Meeting of Shareholders,

-  IW-3718 Phase IIb Data Selected for the Distinguished Abstract Plenary Session - CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 23, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced that the company in collaboration with researchers will present

- Urges Shareholders to Vote "FOR" the Ironwood Director Nominees on the WHITE Proxy Card - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a commercial biotech company, today announced that it has mailed a letter to shareholders highlighting the experience and